Fig. 4: Active compounds protect human β-cells from glucolipotoxicity.

a Overview of compounds included in cellular assays. Table shows results of cytotoxicity and β-cell rescue from glucolipotoxicity in the presence of the compounds (green indicates positive outcome and red cytotoxicity). b Schematic of adaptation to the SPARKL assay in human islets to specifically monitor β-cells. Some elements were made using BioRender.com. c Representative figures from (d) at 48 h with 43. The results are representative from 4 different human cadaveric donors. d Representative kinetics of β-cell death in glucolipotoxicity (20 mM glucose+500 μM palmitate), in the presence of 10 µM of the indicated compounds. e Quantification of β-cell death (assessed by Yoyo3 + % of GFP+ cells) at 24 h from (d). f Human islets were treated for 24 h as indicated, followed by quantification of glucose-stimulated insulin secretion (GSIS) in KREBS buffer (2.8 mM glucose, 1% BSA) over 30 min. The corresponding GSIS-stimulation index (SI) was obtained by determining the ratio of insulin release at high vs low glucose. Data are means +/- SEM; n = 4; p < 0.01**, p < 0.01; ***, p < 0.005; ****, p < 0.001 by 2-Way ANOVA. Source data are provided as a Source Data file.